While many Baby Boomers have enjoyed a long bull market over the past 35 years, there is a point when income becomes more critical than stock appreciation.

HONG KONG, March 24, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK)  ("Akeso" or the "Company") announced today that it has received clearance from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) to initiate Phase II clinical trials for AK146D1, a first-in-class Trop2 /Nectin4 bispecific antibody-drug conjugate (ADC), and AK138D1, an innovative HER3-targeting ADC. The studies will evaluate these two novel ADC candidates in combination with the Company's pioneering immuno-oncology (IO) 2.0 bispecific antibodies, cadonilimab (PD-1/CTLA-4) and ivonescimab (PD-1/VEGF), as well as other proprietary high-potential anti-tumor assets, including AK117 (anti-CD47 monoclonal antibody) and AK109 (anti-VEGF monoclonal antibody), across a spectrum of advanced solid tumors.

ADC's recent pullback left investors wondering whether it's time to buy  more shares or realize profits. ADC's triple net lease model and monthly dividends often draw comparisons to O, yet ADC offers distinct advantages (and one risk compared to O). Recent inflation data and higher-than-expected PPI readings have heightened market concerns, especially for REITs like ADC.

Agree Realty Corporation remains a Buy, supported by a high-quality, diversified net lease portfolio and peer-leading investment-grade tenant exposure. ADC projects 2026 AFFO per share of $4.54–$4.58, targeting 5.4% growth at midpoint, with a robust pipeline and minimal near-term debt maturities. Despite macro headwinds and sector pressure, ADC's strong balance sheet, 99.7% occupancy, and disciplined capital allocation position it for solid returns.

Top REIT investors are quietly repositioning their portfolios, revealing where the “smart money” sees opportunity. Several clear sector themes are emerging from recent 13F filings. But the biggest surprise may be how much top managers disagree on certain REITs.

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced three of the Company's internally-developed investigational oncology therapies will be presented across four poster sessions at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026 taking place April 17-22 in San Diego, California. These next-generation candidates include: zocilurtatug pelitecan (zoci, formerly ZL-1310), a DLL3-targeting antibody-drug conjugate (A.

MORRISTOWN, N.J., March 17, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced it will present three preclinical abstracts, including an oral minisymposium and two posters, highlighting its next-generation antibody-drug conjugate (ADC) portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17–22, 2026, in San Diego, CA.

U.S. equities slid to four-month lows as the escalating Iran war rattled markets, sending oil to three-year highs and interest rates higher amid tanker attacks, shipping disruptions, and intensifying strikes. Brent Crude jumped above $100 as attacks on shipping in the Strait of Hormuz and tanker explosions threatened global oil flows, fueling inflation fears and keeping investors on edge. The White House deployed emergency supply measures—including Russian crude purchases and potential strategic reserve releases—but markets remain skeptical they can offset disruptions to global energy flows.

Engineers Gate Manager LP bought 1,144,617 Agree Realty (ADC) shares Quarter-end position value rose by $82.48 million, reflecting both the share increase and stock price changes This trade represented 0.99% of the fund's 13F reportable assets under management Fund held 1,182,229 ADC shares worth $85.16 million at quarter end The ADC stake now accounts for 1.01% of 13F AUM, which places it outside the fund's top five holdings

Agree Realty and Waste Management are highlighted as defensive, income-focused plays amid rising recession risks and market volatility. ADC boasts a 99.7% occupancy rate, investment-grade tenants, a near 4% yield, and an A-rated balance sheet with no material debt due for two years. WM demonstrates resilient cash flow, a 15% dividend hike, and strategic investments in renewable energy and recycling, targeting 30% FCF growth for 2026.